Miglitol vs Voglibose

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Alpha-glucosidase · full Type 2 Diabetes pipeline

Miglitol · Glyset

Rights held by Bayer and partners

US approval withdrawn in Type 2 Diabetessmall molecule
Partial signal

NCT00213070 · Phase 3 · completed

The study was randomized and double-blind, but the registry does not clearly identify a comparator arm, sample size, or primary endpoint. Because no results are posted, it is not possible to determine whether the primary glycemic endpoint was met.

No aligned efficacy figure on record for this race.

Voglibose

Marketed by T's Pharma and partners

Phase 3 in Type 2 Diabetessmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMiglitolVoglibose
HbA1c, change—Not posted · NCT00380822-0.9% vs -1.0%vs Alogliptin25 mg QD + 0.2 mg TID · wk 12 · n 79NCT01263483
9 other results
  • 0.0% vs -1.0% 0.2 mg TID · wk 12 · n 74 · Phase 2/3 · primary NCT01263483
  • -0.8% vs -0.7% 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.4% vs -0.4% 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.2% vs -0.2% 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.0% vs -0.7% 0.2 mg TID · wk 8 · n 74 · Phase 2/3 · secondary NCT01263483
  • -0.0% vs -0.4% 0.2 mg TID · wk 4 · n 74 · Phase 2/3 · secondary NCT01263483
  • -0.0% vs -0.2% 0.2 mg TID · wk 2 · n 74 · Phase 2/3 · secondary NCT01263483
  • -0.7% vs -0.9% 0.2 mg · wk 12 · n 156 · Phase 4 · primary NCT02049814
  • -0.5% vs -0.6% 0.2 mg · wk 6 · n 156 · Phase 4 · secondary NCT02049814
Body weight, change (kg)—Not posted · NCT00380822-1.2 vs -1.4vs Acarbose0.2 mg · wk 12 · n 156NCT02049814
2 other results
  • -0.6 vs -0.8 0.2 mg · wk 6 · n 156 · Phase 4 · secondary NCT02049814
  • -0.0 vs -0.2 0.2 mg · wk 2 · n 156 · Phase 4 · secondary NCT02049814
HbA1c below 7%—Not posted · NCT00380822—Not reported
Fasting plasma glucose, change—Not posted · NCT00380822-1.0 vs -1.1vs Alogliptin25 mg QD + 0.2 mg TID · wk 12 · n 79NCT01263483
7 other results
  • -1.2 vs -1.1 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.3 vs -0.9 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.0 vs -0.9 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.3 vs -1.1 0.2 mg TID · wk 12 · n 73 · Phase 2/3 · secondary NCT01263483
  • -0.1 vs -1.1 0.2 mg TID · wk 8 · n 73 · Phase 2/3 · secondary NCT01263483
  • -0.0 vs -0.9 0.2 mg TID · wk 4 · n 73 · Phase 2/3 · secondary NCT01263483
  • -0.2 vs -0.9 0.2 mg TID · wk 2 · n 73 · Phase 2/3 · secondary NCT01263483
3-point MACE (% with event)—Not posted · NCT00380822—Not reported

HbA1c, change

Miglitol
—Not posted · NCT00380822
Voglibose
-0.9% vs -1.0%vs Alogliptin25 mg QD + 0.2 mg TID · wk 12 · n 79NCT01263483
9 other results
  • 0.0% vs -1.0% 0.2 mg TID · wk 12 · n 74 · Phase 2/3 · primary NCT01263483
  • -0.8% vs -0.7% 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.4% vs -0.4% 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.2% vs -0.2% 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.0% vs -0.7% 0.2 mg TID · wk 8 · n 74 · Phase 2/3 · secondary NCT01263483
  • -0.0% vs -0.4% 0.2 mg TID · wk 4 · n 74 · Phase 2/3 · secondary NCT01263483
  • -0.0% vs -0.2% 0.2 mg TID · wk 2 · n 74 · Phase 2/3 · secondary NCT01263483
  • -0.7% vs -0.9% 0.2 mg · wk 12 · n 156 · Phase 4 · primary NCT02049814
  • -0.5% vs -0.6% 0.2 mg · wk 6 · n 156 · Phase 4 · secondary NCT02049814

Body weight, change (kg)

Miglitol
—Not posted · NCT00380822
Voglibose
-1.2 vs -1.4vs Acarbose0.2 mg · wk 12 · n 156NCT02049814
2 other results
  • -0.6 vs -0.8 0.2 mg · wk 6 · n 156 · Phase 4 · secondary NCT02049814
  • -0.0 vs -0.2 0.2 mg · wk 2 · n 156 · Phase 4 · secondary NCT02049814

HbA1c below 7%

Miglitol
—Not posted · NCT00380822
Voglibose
—Not reported

Fasting plasma glucose, change

Miglitol
—Not posted · NCT00380822
Voglibose
-1.0 vs -1.1vs Alogliptin25 mg QD + 0.2 mg TID · wk 12 · n 79NCT01263483
7 other results
  • -1.2 vs -1.1 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.3 vs -0.9 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.0 vs -0.9 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.3 vs -1.1 0.2 mg TID · wk 12 · n 73 · Phase 2/3 · secondary NCT01263483
  • -0.1 vs -1.1 0.2 mg TID · wk 8 · n 73 · Phase 2/3 · secondary NCT01263483
  • -0.0 vs -0.9 0.2 mg TID · wk 4 · n 73 · Phase 2/3 · secondary NCT01263483
  • -0.2 vs -0.9 0.2 mg TID · wk 2 · n 73 · Phase 2/3 · secondary NCT01263483

3-point MACE (% with event)

Miglitol
—Not posted · NCT00380822
Voglibose
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Miglitol: no structured comparison results are available for Type 2 Diabetes.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Miglitol: 0 of 4 rows · Voglibose: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricVoglibose
Dropout rate
11.7%0.2 mga
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
—Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
6.3%25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
9.3%0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence
Discontinued due to AEs
3.2%0.2 mga
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
—Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
3.8%25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
5.3%0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence
Serious AEs
1.2%0.2 mga
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
6.7%Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
5.6%Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
1.3%25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
12%0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence
Most frequent reported AEs
0.2 mga
flatulence 9.3%
urinary tract infection 6%
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
Alogliptin 25 mg QD and Voglibose 0.2 mg TID
nasopharyngitis 28.6%
back pain 5.7%
arthralgia 4.8%
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
nasopharyngitis 35.2%
upper respiratory tract inflammation 11.1%
back pain 7.4%
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
25 mg QD + 0.2 mg TID
nasopharyngitis 16.5%
eczema 0%
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
0.2 mg TID
nasopharyngitis 5.3%
eczema 4%
NCT01263483 · Phase 2/3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Voglibose

HbA1c -0.91% (n=79) vs -0.96% (n=76) Alogliptin @ 12wk25 mg QD + 0.2 mg TID
absolute change · percentage points
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
show 9 more results
-0.21% (n=79) vs -0.19% (n=76) Alogliptin @ 2wk25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
-0.43% (n=79) vs -0.44% (n=76) Alogliptin @ 4wk25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
-0.75% (n=79) vs -0.74% (n=76) Alogliptin @ 8wk25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
-0.6982% (n=156) vs -0.9335% (n=156) Acarbose @ 12wk0.2 mg
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
-0.4765% (n=156) vs -0.631% (n=156) Acarbose @ 6wk0.2 mg
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
0.04% (n=74) vs -0.96% (n=76) Alogliptin @ 12wk0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence
-0.01% (n=74) vs -0.19% (n=76) Alogliptin @ 2wk0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence
-0.02% (n=74) vs -0.44% (n=76) Alogliptin @ 4wk0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence
-0.01% (n=74) vs -0.74% (n=76) Alogliptin @ 8wk0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence
Fasting Glucose -0.4234 vs -0.8851 Acarbose mmol/L @ 6wk0.2 mg
absolute change · mmol/L
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-0.5041 vs -0.8029 Acarbose mmol/L @ 12wk0.2 mg
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
Fasting Insulin 0.0319 vs 2.4169 Acarbose μU/dL @ 12wk0.2 mg
absolute change · μU/dL
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
HOMA IR -0.366 vs 0.4983 Acarbose Insulin resistance @ 12wk0.2 mg
absolute change · Insulin resistance
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
HOMA-B 15.3149% (n=156) vs 28.1739% (n=156) Acarbose @ 12wk0.2 mg
absolute change · percentage points
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
Weight -0.016 vs -0.1731 Acarbose kg @ 2wk0.2 mg
absolute change · kg
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
show 2 more results
-0.6315 vs -0.7975 Acarbose kg @ 6wk0.2 mg
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
-1.1563 vs -1.4394 Acarbose kg @ 12wk0.2 mg
NCT02049814 · Phase 4 · registry result, not featured evidence · combination
HbA1c -0.79% (n=100) @ 8wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
absolute change · percentage points
No placebo or comparator arm
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
show 25 more results
-0.96% (n=99) @ 12wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.96% (n=84) @ 16wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.89% (n=83) @ 20wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.88% (n=82) @ 24wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.89% (n=82) @ 28wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.85% (n=82) @ 32wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.9% (n=78) @ 36wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.92% (n=78) @ 40wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.94% (n=51) @ 44wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.94% (n=49) @ 48wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.95% (n=48) @ 52wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.89% (n=105)Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.69% (n=107) @ 8wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.89% (n=106) @ 12wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.91% (n=91) @ 16wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.9% (n=90) @ 20wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.83% (n=90) @ 24wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.81% (n=88) @ 28wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.8% (n=86) @ 32wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.82% (n=84) @ 36wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.78% (n=82) @ 40wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.88% (n=53) @ 44wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.92% (n=53) @ 48wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.95% (n=53) @ 52wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-0.81% (n=108)Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
Fasting Plasma Glucose -1.13 mmol/L @ 8wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
absolute change · mmol/L
No placebo or comparator arm
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -20.4 mg/dL as posted
show 25 more results
-1.04 mmol/L @ 12wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -18.8 mg/dL as posted
-0.85 mmol/L @ 16wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -15.3 mg/dL as posted
-0.83 mmol/L @ 20wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -15 mg/dL as posted
-0.87 mmol/L @ 24wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -15.6 mg/dL as posted
-1.22 mmol/L @ 28wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -21.9 mg/dL as posted
-1.12 mmol/L @ 32wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -20.1 mg/dL as posted
-1.25 mmol/L @ 36wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -22.6 mg/dL as posted
-1.27 mmol/L @ 40wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -22.8 mg/dL as posted
-1.35 mmol/L @ 44wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -24.4 mg/dL as posted
-1.28 mmol/L @ 48wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -23.1 mg/dL as posted
-1.33 mmol/L @ 52wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -24 mg/dL as posted
-1.29 mmol/L*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -23.3 mg/dL as posted
-1.01 mmol/L @ 8wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -18.2 mg/dL as posted
-0.95 mmol/L @ 12wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.1 mg/dL as posted
-0.89 mmol/L @ 16wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -16 mg/dL as posted
-0.87 mmol/L @ 20wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -15.6 mg/dL as posted
-0.77 mmol/L @ 24wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -13.8 mg/dL as posted
-0.8 mmol/L @ 28wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -14.5 mg/dL as posted
-0.98 mmol/L @ 32wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.7 mg/dL as posted
-0.96 mmol/L @ 36wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.3 mg/dL as posted
-1.09 mmol/L @ 40wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -19.7 mg/dL as posted
-1.19 mmol/L @ 44wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -21.5 mg/dL as posted
-1.14 mmol/L @ 48wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -20.5 mg/dL as posted
-1.15 mmol/L @ 52wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -20.7 mg/dL as posted
-0.97 mmol/L*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.5 mg/dL as posted
PPG 2h Change mg/dL 2.09 mmol/L @ 12wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
absolute change · mmol/L
No placebo or comparator arm
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 37.6 mg/dL as posted
show 7 more results
2.06 mmol/L @ 24wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 37.1 mg/dL as posted
2.26 mmol/L @ 52wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 40.8 mg/dL as posted
2.19 mmol/L*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 39.4 mg/dL as posted
2.29 mmol/L @ 12wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 41.2 mg/dL as posted
2.11 mmol/L @ 24wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 38 mg/dL as posted
2.16 mmol/L @ 52wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 39 mg/dL as posted
2.2 mmol/L*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 39.6 mg/dL as posted
PPG AUC Change Mgmin dL -76.8 mg @ 12wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
absolute change · mg
No placebo or comparator arm
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
show 7 more results
-70.4 mg @ 24wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-83.4 mg @ 52wkAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-82.2 mgAlogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-73.2 mg @ 12wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-69 mg @ 24wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-83.5 mg @ 52wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
-77.5 mgAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
Fasting Plasma Glucose -1.04 vs -0.86 Alogliptin mmol/L @ 2wk25 mg QD + 0.2 mg TID
absolute change · mmol/L
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -18.8 mg/dL as posted
show 7 more results
-1.25 vs -0.9 Alogliptin mmol/L @ 4wk*25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -22.6 mg/dL as posted
-1.22 vs -1.15 Alogliptin mmol/L @ 8wk*25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -21.9 mg/dL as posted
-1.03 vs -1.06 Alogliptin mmol/L @ 12wk*25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -18.5 mg/dL as posted
-0.19 vs -0.86 Alogliptin mmol/L @ 2wk*0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · converted to mmol/L from -3.5 mg/dL as posted
-0.03 vs -0.9 Alogliptin mmol/L @ 4wk*0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · converted to mmol/L from -0.6 mg/dL as posted
-0.14 vs -1.15 Alogliptin mmol/L @ 8wk*0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · converted to mmol/L from -2.5 mg/dL as posted
-0.31 vs -1.06 Alogliptin mmol/L @ 12wk*0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · converted to mmol/L from -5.6 mg/dL as posted
PPG 2h Change mg/dL 2.15 vs 2.27 Alogliptin mmol/L @ 12wk25 mg QD + 0.2 mg TID
absolute change · mmol/L
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 38.7 mg/dL as posted
show 1 more result
4.02 vs 2.27 Alogliptin mmol/L @ 12wk*0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · converted to mmol/L from 72.4 mg/dL as posted

+ 1 further endpoint in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Miglitol's landscape · Voglibose's landscape